Summary

for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.

Official Title

A Phase 1 Study of LY3200882 in Patients With Solid Tumors

Keywords

Solid Tumor TGF Beta Paclitaxel Gemcitabine Albumin-Bound Paclitaxel Cisplatin LY3200882 LY3300054 nab-Paclitaxel Intensity Modulated Radiotherapy LY3200882 Schedule 1 Escalation LY3200882 Schedule 2 Escalation LY3200882 Schedule 1 Expansion LY3200882 Schedule 2 Expansion LY3200882 + Gemcitabine + nab-Paclitaxel LY3200882 + Cisplatin + Radiation

Eligibility

You can join if…

Open to people ages 18 years and up

  • The participant must have histological or cytological evidence of cancer.
  • Have adequate organ function.
  • Have Eastern Cooperative Oncology Group (ECOG) scale performance status of 0 or 1.
  • Are able to swallow capsules and tablets.

You CAN'T join if...

  • Have moderate or severe cardiovascular disease.
  • Have a serious concomitant systemic disorder.
  • Have acute leukemia.

Locations

  • University of California, San Francisco not yet accepting patients
    San Francisco California 94115 United States
  • University of Texas MD Anderson Cancer Center accepting new patients
    Houston Texas 77030 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Eli Lilly and Company
Links
Click here for more information about this study: A Study of LY3200882 in Participants With Solid Tumors
ID
NCT02937272
Phase
Phase 1
Study Type
Interventional
Last Updated
September 11, 2018